Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 6/20 | 0.52 |
| ▸ | ACLY | P53396 | 5/20 | 0.49 |
| ▸ | CCR9 | P51686 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13852833 | 0.88 | HSD17B2 (0.63) | HSD17B2CCR9ALDH1A1CCR2 | |
| SCHEMBL13852821 | 0.87 | PKM (0.56) | HSD17B2CCR9ALDH1A1 | |
| SCHEMBL13852837 | 0.82 | HSD17B2 (0.68) | HSD17B2ALDH1A1 | |
| SCHEMBL13615244 | 0.80 | NHERF1 (0.65) | HSD17B2ACLYALDH1A1 | |
| SCHEMBL13852847 | 0.80 | ACLY (0.53) | HSD17B2ACLYCCR9 | |
| SCHEMBL13615288 | 0.79 | HSD17B2 (0.57) | HSD17B2 | |
| SCHEMBL13629419 | 0.78 | NPC1 (0.49) | ACLYALDH1A1 | |
| SCHEMBL13852823 | 0.78 | MCL1 (0.59) | HSD17B2ACLYALDH1A1 | |
| SCHEMBL13615292 | 0.78 | MCL1 (0.57) | HSD17B2ACLYCCR9ALDH1A1 | |
| SCHEMBL15248886 | 0.78 | HSD17B2 (0.74) | HSD17B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | HSD17B2 4198/4885ACLY 2087/4885CCR9 3942/4885 |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | HSD17B2 4325/4885ACLY 2202/4885CCR9 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.